Back to Directory
Synairgen
Founded 2003
No longer trading
This company ceased operations and entered members' voluntary liquidation (2026).
Inhaled interferon beta therapy for severe viral lung infections
Synairgen is a clinical-stage biopharmaceutical company developing an inhaled formulation of interferon beta as a broad-spectrum antiviral therapy for severe respiratory viral infections.
The approach stimulates the innate immune response directly in the lungs, targeting patients with severe viral pneumonia including those requiring mechanical ventilation.
A Phase 2 randomised controlled trial is currently enrolling patients across intensive care units in the UK, US, and Europe.